Mankind Pharma Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 14, 2026 3 min read

Mankind Pharma approaches its Q4 results following a period of balanced growth across its domestic prescription business and strategic acquisitions. Investors will be focused on the company's ability to maintain its 25-26% EBITDA margin guidance and the progress made in de-leveraging its balance sheet.

Quick Details

Results date	2026-05-19
Quarter	Q4
Previous quarter revenue	Rs. 3,567 Cr
Previous quarter PAT	Rs. 414 Cr
Previous quarter EBITDA margin	25.9%
Net debt (latest quarter)	Rs. 4,294 Cr
Market cap	Rs. 100,185.19 Cr
CMP	Rs. 2,426.8

Mankind Pharma Limited Q4 Results Date and Time

The board meeting is scheduled for May 19, 2026, to approve the Q4 and FY26 audited financial results and discuss NCD security cover realignment.

An investor conference call is scheduled for May 20, 2026, from 12:00 PM to 1:00 PM IST to discuss the Q4 and FY26 results.

What to expect from Mankind Pharma Limited's Q4 FY26 results

In its most recently reported quarter, Mankind Pharma posted revenue of Rs. 3,567 Cr, PAT of Rs. 414 Cr, and an EBITDA margin of 25.9%. The company continues to see strong momentum in chronic therapies, with cardiovascular and anti-diabetic segments growing at 16.7% and 14.4% respectively in Q3. Management maintains a focus on strengthening the balance sheet, having reduced net debt to Rs. 4,294 Cr as of December 31, 2025, while targeting a net debt to adjusted EBITDA ratio of 1.1x-1.2x by the end of FY26. The upcoming call will likely address the integration of the Rivotril brand acquired in March 2026 and the operational efficiency gains from the BSV sales force optimization.

Key Things To Watch

Performance vs Guidance Tracking

EBITDA margin guidance of 25-26% for FY26 — 25.9% achieved in Q3
Domestic revenue growth target of 1.2x IPM — 1.2x achieved in Q3
Net debt/EBITDA target of 1.1-1.2x by end of FY26 — 1.3x reported in Q3
BSV growth guidance of 18-20% for FY26 — on track
CAPEX guidance of 4-5% of revenue — 4.4% achieved in 9MFY26

Strategic execution and portfolio expansion

Progress on CNS portfolio enhancement post-Rivotril acquisition from Roche
Update on Phase 2 trials for GPR119 and biosimilar facility construction in Baroda
Path to exceeding 40% chronic therapy share in the short to mid-term

Operating metric trajectory

Sustained improvement in CFO/EBITDA ratio (93% in 9MFY26 vs 68% in 9MFY25)
Competitive pricing strategy maintaining a notch lower than IPM price increases
Recovery of acute segment growth following previous restructuring

Risks and headwinds to monitor

Updates regarding the GST Department search conducted at BSV in February 2026
Impact of GLP-1 genericization on the anti-diabetic portfolio

Frequently Asked Questions

When will Mankind Pharma announce Q4 FY 2025-2026 results?

Mankind Pharma will announce its Q4 FY 2025-2026 results on May 19, 2026.

What was Mankind Pharma's revenue in its previous quarter?

Mankind Pharma reported revenue of Rs. 3,567 Cr in the third quarter of FY 2025-2026.

What is Mankind Pharma's net debt position?

As of December 31, 2025, Mankind Pharma's net debt stood at Rs. 4,294 Cr. This reflects a reduction from Rs. 5,249 Cr at the start of the financial year.

When does Mankind Pharma expect its chronic therapy share to exceed 40%?

Management projects the chronic therapy share to exceed 40% in the short to mid-term. As of Q4 FY25, the share stood at 39.2%.

Is Mankind Pharma on track with its FY26 EBITDA margin guidance?

Yes, the company is on track with its FY26 EBITDA margin guidance of 25-26%. It delivered an adjusted EBITDA margin of 25.9% in the most recent quarter.